clinical trial · NCT07571174
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly and Company·phase1·not yet recruiting·n = 32
Amyotrophic Lateral SclerosisLY4256984
brief summary
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.
started
May 1, 2026
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
May 13, 2026
official title
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol